/
CMPX
$2.16+$0.08 (+3.85%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$374.6M
180M shares
52-week range
$1.61 – $6.88
10% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.82
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $850.0K | $0 |
| Cost of revenue | $1.9M | $0 | $0 | $0 | $0 | $0 | $0 | $1.5M |
| Gross profit | −$1.9M | $0 | $0 | $0 | $0 | $0 | $850.0K | −$1.5M |
| Gross margin | — | — | — | — | — | — | 100.0% | — |
| R&D | $27.1M | $22.4M | $14.9M | $20.3M | $30.0M | $38.1M | $42.3M | $56.0M |
| Operating income | −$38.3M | −$34.1M | −$27.8M | −$81.9M | −$41.7M | −$50.4M | −$56.6M | −$72.8M |
| EBITDA | −$35.7M | −$31.9M | −$25.4M | −$80.2M | −$35.0M | −$40.6M | −$47.6M | −$65.0M |
| Net income | −$38.3M | −$34.7M | −$29.5M | −$82.2M | −$39.2M | −$42.5M | −$49.4M | −$66.5M |
| Net margin | — | — | — | — | — | — | -5808.8% | — |
| EPS (diluted) | -7.66 | -0.67 | -0.52 | -1.31 | -0.35 | -0.33 | -0.36 | -0.42 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $-2M | $-0.44 | $-0.47–$-0.34 | 11 |
| 2027 | $26M | $-0.46 | $-0.69–$-0.22 | 10 |
| 2028 | $127M | $-0.14 | $-0.67–$0.32 | 12 |
| 2029 | $264M | $0.30 | $0.07–$0.68 | 10 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.12
Price
$2.16
Implied downside
-94%
Peer comparison
Compass Therapeutics, Inc. Common Stock
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
www.compasstherapeutics.com- Employees
- 39
- IPO / List date
- Nov 13, 2020
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds CMPX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 79,000 | $276.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CMPX yet.
